Toth Financial Advisory Corp Tcr2 Therapeutics Inc. Transaction History

Toth Financial Advisory Corp

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 31, 2022	SELL	$4.58 - $8.34 $229 - $417	-50 Closed	0 $0
Q1 2021 Apr 20, 2021	BUY	$20.38 - $34.07 $1,019 - $1,703	50 New	50 $1,000
Q4 2020 Jan 25, 2021	SELL	$19.0 - $32.63 $2,850 - $4,894	-150 Closed	0 $0
Q3 2019 Oct 15, 2019	BUY	$10.15 - $19.53 $1,522 - $2,929	150 New	150 $2,000

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Toth Financial Advisory Corp, based on Form 13F filings with the SEC.

Stay updated on Toth Financial Advisory Corp with notifications on news.